Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 336

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

Open access
Sano, M., Bell, K.L., Galasko, D., Galvin, J.E., Thomas, R.G., van Dyck, C.H., Aisen, P.S. · 2011 · Neurology

Abstract

Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG - CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, supporting the hypothesis that statin therapy is useful in the treatment of AD. Objective: To determine if the lipid-lowering agent simvastatin slows the progression of symptoms in AD. Methods: This randomized, double-blind, placebo-controlled trial of simvastatin was conducted in individuals with mild to moderate AD and normal lipid levels. Participants were randomly assigned to receive simvastatin, 20 mg/day, for 6 weeks then 40 mg per day for the remainder of 18 months or identical placebo. The primary outcome was the rate of change in the Alzheimer's Disease Assessment Scale–cognitive portion (ADAS-Cog). Secondary outcomes measured clinical global change, cognition, function, and behavior. Results: A total of 406 individuals were randomized: 204 to simvastatin and 202 to placebo. Simvastatin lowered lipid levels but had no effect on change in ADAS-Cog score or the secondary outcome measures. There was no evidence of increased adverse events with simvastatin treatment. Conclusion: Simvastatin had no benefit on the progression of symptoms in individuals with mild to moderate AD despite significant lowering of cholesterol. Classification of evidence: This study provides Class I evidence that simvastatin 40 mg/day does not slow decline on the ADAS-Cog. Aβ= : amyloid β peptide; AChE= : acetylcholinesterase; AD= : Alzheimer disease; ADAS-Cog= : Alzheimer's Disease Assessment Scale–cognitive portion; ADCS= : Alzheimer's Disease Cooperative Study; ADCS-ADL= : Alzheimer's Disease Cooperative Study Activities of Daily Living; ADCS-CGIC= : Alzheimer's Disease Cooperative Study Clinical Global Impression of Change; ADCS-RUI= : Alzheimer's Disease Cooperative Study Resource Use Instrument; ALT= : alanine aminotransferase; AST= : aspartate aminotransferase; ATP= : Adult Treatment Panel; CRP= : C-reactive protein; GEE= : generalized estimating equation; HDL= : high-density lipoprotein; HMG-CoA= : 3-hydroxy-3-methylglutaryl coenzyme A; ITT= : intent-to-treat; LDL= : low-density lipoprotein; MMSE= : Mini-Mental State Examination; NPI= : Neuropsychiatric Inventory; QOL= : quality of life

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e318228bf11

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 336

Metadata

Authors
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S.
Venue
Neurology
Published
2011-08-09
Volume
77
Issue
6
Pages
556-563
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2147048440
Cited by
336
References
43
FWCI
16.37
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0b013e318228bf11
The paper
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. (2011). A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0b013e318228bf11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.